Left Ventricular Dilatation and Posterior Papillary Muscle Displacement in an Ex Vivo Pulsatile Model of Functional Mitral Regurgitation
Background: Surgical method of choice for functional mitral regurgitation (FMR) is debatable, since recurrence of FMR post-annuloplasty has been reported in a significant number of cases. Developing a pulsatile FMR heart model by left ventricular dilatation can be a favorable option for usage in the primary stages of developing new surgical techniques that adjunctively targets the posterior papillary muscle (PPM) geometry.
Methods: PPM of ex vivo ovine hearts (N = 22) was displaced by three different sizes of patches to induce left ventricular dilatation and FMR. Mitral regurgitation (MR) flow, left ventricular and annular geometry were measured from the dynamic pulsatile flow system before and after patch placement.
Results: Outward displacement of PPM was significantly increased in all patch sizes compared to baseline (P = .016,
P = .031, and P = .008 from small to large patch, respectively). Left ventricular volume (LVV) significantly increased from 18.53 (15.01-26.03) mL at baseline to 27.5 (19.45-42.46) mL after large patch placement (P = .031). However, the small and medium patch groups did not show significant changes in the LVV after patch placement. MR significantly increased 554 (185-1,919.3) mL/min after applying the large patch compared to baseline (P = .016). There were no significant changes from baseline in MR flow after applying the small and medium patch. Application of the large patch produced the highest proportion of FMR heart models (87.5%, P = .031).
Conclusion: The large patch ex vivo pulsatile heart model demonstrated outward displacement of the PPM and significantly produced MR flow. This ex vivo pulsatile heart model can be used to facilitate surgical techniques that targets the PPM displacement in FMR patients.
Braun J, Klautz RJM. 2012. Mitral valve surgery in low ejection fraction, severe ischemic mitral regurgitation patients: should we repair them all? Curr Opin Cardiol 27:111-–7.
Capoulade R, Zeng X, Overbey JR, et al. 2016. Impact of Left Ventricular to Mitral Valve Ring Mismatch on Recurrent Ischemic Mitral Regurgitation After Ring Annuloplasty. Circulation 134:1247-56.
Enriquez-Sarano M, Akins CW, Vahanian A. 2009. Mitral regurgitation. The Lancet 373:1382–94.
Gorman III M, Gorman RC, Jackson BM, et al. 1997. Distortions of the Mitral Valve in Acute Ischemic Mitral Regurgitation. Ann Thorac Surg 64:1026–1031.
Green GR, Dagum P, Glasson JR, et al. 1999. Mitral Annular Dilatation and Papillary Muscle Dislocation Without Mitral Regurgitation in Sheep. Circulation 100:II95–II102.
He S, Fontaine AA, Schwammenthal E, Yoganathan AP, Levine RA. 1997. Integrated Mechanism for functional mitral regurgitation. Circulation 96:1826-1834.
Hung J, Solis J, Handschumacher MD, et al. 2012. Persistence of mitral regurgitation following ring annuloplasty: is the papillary muscle outside or inside the ring? J Heart Valve Dis 21(2):218-24.
Jensen H, Jensen MO, Smerup MH, et al. 2010. Three-dimensional assessment of papillary muscle displacement in a porcine model of ischemic mitral regurgitation. J Thorac Cardiovasc Surg 140:1312-8.
Kalra K, Wang Q, McIver BV, et al. 2014. Temporal changes in interpapillary muscle dynamics as an active indicator of mitral valve and left ventricular interaction in ischemic mitral regurgitation. J Am Coll Cardiol 64(18):1867-79.
Katoh T, Ikeda N, Nishi K, et al. 1999. A Newly Designed Adapter for Testing an Ex Vivo Mitral Valve Apparatus. Artificial Organs 23:920–3.
Kono T, Sabbah HN, Rosman H, Alam M, Jafri S, Goldstein S. 1992. Left ventricular shape is the primary determinant of functional mitral regurgitation in heart failure. J Am Coll Cardiol 20:1594–1598.
Kumanohoso T, Otsuji Y, Yoshifuku S, et al. 2003. Mechanism of higher incidence of ischemic mitral regurgitation in patients with inferior myocardial infarction: quantitative analysis of left ventricular and mitral valve geometry in 103 patients with prior myocardial infarction. J Thorac Cardiovasc Surg 125:135–43.
Kwan J, Shiota T, Agler DA, et al. 2003. Geometric Differences of the Mitral Apparatus Between Ischemic and Dilated Cardiomyopathy With Significant Mitral Regurgitation Real-Time Three-Dimensional Echocardiography Study. Circulation 107:1135–40.
McGee J, Edwin C, Gillinov AM, et al. 2004. Recurrent mitral regurgitation after annuloplasty for functional ischemic mitral regurgitation. J Thorac Cardiovasc Surg 128:916–24.
Monnet E and Pouching K. 2013. An ex vivo model of left ventricular dilation and functional mitral regurgitation to facilitate the development of surgical techniques. The Heart Surgery Forum 16(6): 332-38.
Otsuji Y, Levine RA, Takeuchi M, Sakata R, Tei C. 2008. Mechanism of ischemic mitral regurgitation. J Cardiol 51:145–156.
Perloff JK, Roberts WC. 1972. The mitral apparatus functional anatomy of mitral regurgitation. Circulation 46:227–239.
Richards AL, Cook RC, Bolotin G, Buckner GD. 2009. A Dynamic Heart System to Facilitate the Development of Mitral Valve Repair Techniques. Ann Biomed Eng 37:651–60.
Sabbah HN, Kono T, Rosman H, Jafri S, Stein PD, Goldstein S. 1992. Left ventricular shape: A factor in the etiology of functional mitral regurgitation in heart failure. Am Heart J 123:961–966.
Siefert AW, Rabbah JPM, Koomalsingh KJ, Touchton SA Jr, Saikrishnan N, McGarvey JR. 2013. In Vitro Mitral Valve Simulator Mimics Systolic Valvular Function of Chronic Ischemic Mitral Regurgitation Ovine Model. Ann Thorac Surg 95:825–30.
Tibayan FA, Rodriguez F, Zasio MK, et al. 2003. Geometric Distortions of the Mitral Valvular-Ventricular Complex in Chronic Ischemic Mitral Regurgitation. Circulation 108:II–116–II–121.
Uemura T, Otsuji Y, Nakashiki K, et al. 2005. Papillary muscle dysfunction attenuates ischemic mitral regurgitation in patients with localized basal inferior left ventricular remodeling: insights from tissue Doppler strain imaging. J Am Coll Cardiol 46:113-9.
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).